Cyberonics setback
This article was originally published in The Gray Sheet
Executive Summary
Amended PMA supplement for depression treatment with VNS vagus nerve stimulation will be submitted following receipt of a "deficiency letter" being prepared by FDA that raises safety, efficacy, clinical significance and trial design issues, the firm reports. The announcement follows a Feb. 4 meeting with the agency on the ongoing review of an October 2003 PMA supplement. After moving up its approval timetable in January, Cyberonics is now reverting to initial projections of a panel review this summer leading to approval by October (1"The Gray Sheet" Jan. 12, 2004, p. 8). Weak U.S. VNS epilepsy sales resulted in fiscal Q3 (ended Jan. 23) revenue of $28.4 mil., ahead 3% - but 10% lower than expectations. Earnings were off 62.5% to $1.6 mil. Cyberonics has reduced its sales force by 27 and plans a total force of under 175 to launch the depression indication later this year - down from estimates of 292 earlier this year...
You may also be interested in...
Cyberonics Moves Up VNS Depression Timetable Four Months; Costs Rise
Cyberonics is preparing for an April FDA panel review of its VNS Therapy vagus nerve stimulation device for depression
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.